FDCDDQ
NBIX icon

Federation des caisses Desjardins du Quebec’s Neurocrine Biosciences NBIX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.03M Buy
23,904
+15,340
+179% +$2.28M 0.01% 580
2026
Q1 		$1.13M Sell
8,564
-95,543
-92% -$12.7M ﹤0.01% 956
2025
Q4 		$14.8M Buy
104,107
+633
+0.6% +$91.7K 0.06% 223
2025
Q3 		$14.5M Sell
103,474
-9,656
-9% -$1.31M 0.06% 219
2025
Q2 		$14.2M Sell
113,130
-2,530
-2% -$290K 0.06% 208
2025
Q1 		$12.8M Sell
115,660
-11,507
-9% -$1.46M 0.06% 206
2024
Q4 		$17.4M Sell
127,167
-12,336
-9% -$1.53M 0.09% 168
2024
Q3 		$16.1M Buy
139,503
+29,768
+27% +$4.08M 0.08% 176
2024
Q2 		$15.1M Sell
109,735
-3,629
-3% -$498K 0.08% 178
2024
Q1 		$15.6M Sell
113,364
-58,404
-34% -$7.98M 0.11% 161
2023
Q4 		$22.6M Sell
171,768
-4,645
-3% -$535K 0.21% 112
2023
Q3 		$19.8M Buy
176,413
+1,998
+1% +$210K 0.2% 112
2023
Q2 		$16.4M Buy
174,415
+164,905
+1,734% +$16.1M 0.16% 131
2023
Q1 		$963K Buy
9,510
+8,207
+630% +$854K 0.01% 607
2022
Q4 		$156K Buy
1,303
+333
+34% +$39K ﹤0.01% 1124
2022
Q3 		$103K Hold
970
– – ﹤0.01% 1307
2022
Q2 		$94.6K Buy
+970
New +$89.5K ﹤0.01% 1360
2021
Q2 		– Sell
-415
Closed -$40.4K – 2554
2021
Q1 		$40.4K Hold
415
– – ﹤0.01% 1608
2020
Q4 		$39.8K Buy
415
+412
+13,733% +$39.8K ﹤0.01% 1553
2020
Q3 		$288 Buy
+3
New +$347 ﹤0.01% 2104
2020
Q2 		– Sell
-8
Closed -$692 – 2216
2020
Q1 		$692 Hold
8
– – ﹤0.01% 2090
2019
Q4 		$860 Hold
8
– – ﹤0.01% 2210
2019
Q3 		$721 Buy
+8
New +$747 ﹤0.01% 2174
2018
Q4 		– Sell
-778
Closed -$95.7K – 2121
2018
Q3 		$95.7K Buy
+778
New +$88.3K ﹤0.01% 1197
2018
Q2 		– Sell
-475
Closed -$39.4K – 2213
2018
Q1 		$39.4K Buy
+475
New +$40.1K ﹤0.01% 1392

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's NBIX Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec increased its Neurocrine Biosciences (NBIX) stake by 179% in Q2 2026, buying an estimated $2.28M and bringing the position to 23,904 shares worth $4.03M. The position accounts for 0.01% of the portfolio, ranked #580.

Federation des caisses Desjardins du Quebec first reported a position in NBIX in Q1 2018 and has held it in 25 quarters since. The position peaked at $22.6M in Q4 2023. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Federation des caisses Desjardins du Quebec held 23,904 shares of Neurocrine Biosciences worth $4.03M as of Q2 2026.
  • Federation des caisses Desjardins du Quebec bought 15,340 Neurocrine Biosciences shares in Q2 2026, an estimated $2.28M.
  • Neurocrine Biosciences made up 0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #580 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 25 quarters since.
  • Federation des caisses Desjardins du Quebec's Neurocrine Biosciences position peaked at $22.6M in Q4 2023.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.